REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/31/2025
Back to search
Official data from USPTO
HEIDELBERG PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
04/01/2025
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
08/03/2018
Registration date
03/31/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/31/2020
Last transaction
04/01/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Ladenburg, DE
Examiner
KEATING, MICHAEL
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a blue circle within another light blue partial circular design, to the right of which appears the stylized word "Heidelberg" in blue letters. Appearing within the partial circular design, and under the word "Heidelberg" is the stylized word "PHARMA" in blue upper-case letters.
Holders and representatives
Holders
Heidelberg Pharma AG
Representatives
Todd A. Sullivan Hayes Soloway P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biochemicalsmonoclonal antibodies for in vitro scientific or research use
Class 5
Pharmaceutical preparations for the treatment of immuno oncological disorderscancer; pharmaceuticals for cancer therapy; chemico-pharmaceutical preparations for cancer therapies; pharmaceutical preparations and substances for use in the treatment of cancer; chemical preparations for pharmaceutical purposesfor the treatment of cancer; pharmaceutical preparations for human usefor the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; clinical diagnostic reagents; diagnostic chemical reagents for medical use; anti-cancer drugs; compounds for treating cancer; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing
Class 42
Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; laboratory services relating to the production of monoclonal antibodies
Class 44
Pharmaceutical advice; pharmaceutical servicesproviding pharmaceutical advice and consultation and dispensing drugs to patients with cancer; consultancy and medical information services relating to pharmaceutical products
Publications
History of USPTO decisions and trademark events.
38 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/04/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/05/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/05/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/05/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/05/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/05/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/14/2020
PUBO
PUBLISHED FOR OPPOSITION
01/14/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/12/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
12/12/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/12/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
12/12/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/12/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/18/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/18/2019
ALIE
ASSIGNED TO LIE
11/16/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/11/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/09/2019
GNRT
NON-FINAL ACTION E-MAILED
05/09/2019
CNRT
NON-FINAL ACTION WRITTEN
05/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/26/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/26/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/26/2018
GNRT
NON-FINAL ACTION E-MAILED
11/26/2018
CNRT
NON-FINAL ACTION WRITTEN
11/26/2018
DOCK
ASSIGNED TO EXAMINER
11/21/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2018
NWAP
NEW APPLICATION ENTERED
08/07/2018
Continuous trademark protection
Get notified about every new filing that threatens HEIDELBERG PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.